DeepMed Research

Efalizumab

Generic Name: Efalizumab

Drug Type: Biotech

CAS Number: 214745-43-4

Unique Ingredient Identifier: XX2MN88N5D

Background: Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).

Indication: For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.

Associated Conditions: Moderate to Severe Chronic Plaque Psoriasis

Clinical Trials

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

Phase 1

Withdrawn

Conditions: Autoimmune Diseases

Interventions: Drug: Efalizumab

First Posted Date: 2008-10-22

Last Posted Date: 2013-05-14

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00777400

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Efalizumab in the Treatment of Alopecia, Phase II

Phase 2

Withdrawn

Conditions: Alopecia Totalis

Interventions: Drug: efalizumab

First Posted Date: 2008-09-04

Last Posted Date: 2016-06-14

Lead Sponsor: Northwestern University

Registration Number: NCT00746980

TRUST Study: Raptiva ® in Hand & Foot Psoriasis

Phase 4

Terminated

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Efalizumab - anti CD11a recombinant human monoclonal antibody

First Posted Date: 2008-08-22

Last Posted Date: 2014-02-27

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 76

Registration Number: NCT00739882

Locations: 🇦🇹
University of Vienna Medical School, Vienna, Austria

Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab

Phase 2

Withdrawn

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: placebo
Drug: efalizumab

First Posted Date: 2008-08-20

Last Posted Date: 2014-05-12

Lead Sponsor: Emory University

Registration Number: NCT00737763

A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

Phase 2

Withdrawn

Conditions: Kidney Transplantation

Interventions: Drug: basiliximab
Drug: efalizumab
Drug: mycophenolate mofetil
Drug: corticosteroids
Drug: cyclosporine

First Posted Date: 2008-08-07

Last Posted Date: 2017-06-22

Lead Sponsor: Genentech, Inc.

Registration Number: NCT00729768

Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis

Phase 4

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: efalizumab plus acitretin
Drug: efalizumab plus placebo

First Posted Date: 2008-06-30

Last Posted Date: 2008-06-30

Lead Sponsor: Universita di Verona

Target Recruit Count: 100

Registration Number: NCT00707070

Locations: 🇮🇹
Univeristy Hospital, Verona, Italy

ChangE From Any Systemic psoriasiS therapY to Raptiva

Phase 4

Terminated

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)

First Posted Date: 2008-06-16

Last Posted Date: 2014-02-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 70

Registration Number: NCT00697593

Locations: 🇨🇦
Probity Medical Research, City Waterloo, Ontario, Canada

Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study

Phase 1

Withdrawn

Conditions: Diabetic Macular Edema

Interventions: Drug: Efalizumab
Drug: Ranibizumab

First Posted Date: 2008-05-13

Last Posted Date: 2016-08-26

Lead Sponsor: Johns Hopkins University

Registration Number: NCT00676559

Locations: 🇺🇸
Sharp Rees-Stealy Medical Group, San Diego, California, United States
🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸
Eye Care Specialists, Kingston, Pennsylvania, United States

and more 7 locations

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Phase 1

Terminated

Conditions: Type 1 Diabetes Mellitus
Hypoglycemia

Interventions: Biological: Allogeneic islets of Langerhans transplant
Drug: Raptiva
Drug: Sirolimus
Drug: anti-thymocyte globulin

First Posted Date: 2008-05-06

Last Posted Date: 2017-10-25

Lead Sponsor: University of Minnesota

Target Recruit Count: 23

Registration Number: NCT00672204

Locations: 🇺🇸
Universtiy of Minnesota, Minneapolis, Minnesota, United States

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: placebo
Drug: efalizumab

First Posted Date: 2008-04-30

Last Posted Date: 2017-06-06

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 89

Registration Number: NCT00669214

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy